About immunovant inc - IMVT
Immunovant, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling normal lives for patients with autoimmune diseases. It is developing a novel, fully human monoclonal antibody IMVT-1401 that selectively binds to and inhibits the neonatal fragment crystallizable receptor. The company was founded in 2018 and is headquartered in Durham, NC.
IMVT At a Glance
Immunovant, Inc.
1000 Park Forty Plaza
Durham, North Carolina 27713
| Phone | 1-917-580-3099 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -413,840,000.00 | |
| Sector | Health Technology | Employees | 362 | |
| Fiscal Year-end | 03 / 2026 | |||
| View SEC Filings |
IMVT Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 4.109 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -4.286 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.00 |
IMVT Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,143,204.42 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
IMVT Liquidity
| Current Ratio | 11.162 |
| Quick Ratio | 11.162 |
| Cash Ratio | 10.381 |
IMVT Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -57.317 |
| Return on Equity | -62.457 |
| Return on Total Capital | -58.49 |
| Return on Invested Capital | -62.457 |
IMVT Capital Structure
| Total Debt to Total Equity | 0.014 |
| Total Debt to Total Capital | 0.014 |
| Total Debt to Total Assets | 0.013 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |